Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:BCRX NASDAQ:CABA NASDAQ:HARP NASDAQ:PDLI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.07+49.2%$0.10$0.04▼$0.86$19.22M2.4936.42 million shs445.07 million shsBCRXBioCryst Pharmaceuticals$7.08+1.3%$7.78$6.00▼$11.31$1.49B1.053.94 million shs6.20 million shsCABACabaletta Bio$2.45-10.6%$2.06$0.99▼$5.46$224.09M3.011.95 million shs3.90 million shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/APDLIPDL BioPharma$2.47$2.47$2.09▼$3.86N/AN/AN/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-17.63%-69.63%-66.34%-83.24%-94.10%BCRXBioCryst Pharmaceuticals+0.87%+8.88%-9.22%-18.82%-7.05%CABACabaletta Bio-2.84%-5.19%+25.11%+71.25%-39.38%HARPHarpoon Therapeutics0.00%0.00%0.00%0.00%0.00%PDLIPDL BioPharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.07+49.2%$0.10$0.04▼$0.86$19.22M2.4936.42 million shs445.07 million shsBCRXBioCryst Pharmaceuticals$7.08+1.3%$7.78$6.00▼$11.31$1.49B1.053.94 million shs6.20 million shsCABACabaletta Bio$2.45-10.6%$2.06$0.99▼$5.46$224.09M3.011.95 million shs3.90 million shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/APDLIPDL BioPharma$2.47$2.47$2.09▼$3.86N/AN/AN/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-17.63%-69.63%-66.34%-83.24%-94.10%BCRXBioCryst Pharmaceuticals+0.87%+8.88%-9.22%-18.82%-7.05%CABACabaletta Bio-2.84%-5.19%+25.11%+71.25%-39.38%HARPHarpoon Therapeutics0.00%0.00%0.00%0.00%0.00%PDLIPDL BioPharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 1.88Reduce$1.351,764.37% UpsideBCRXBioCryst Pharmaceuticals 2.77Moderate Buy$19.18170.93% UpsideCABACabaletta Bio 2.82Moderate Buy$13.44448.75% UpsideHARPHarpoon Therapeutics 0.00N/AN/AN/APDLIPDL BioPharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HARP, BCRX, ADAP, CABA, and PDLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025BCRXBioCryst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$24.00 ➝ $26.0010/15/2025BCRXBioCryst PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.0010/15/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $20.0010/15/2025BCRXBioCryst PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$17.00 ➝ $27.0010/10/2025CABACabaletta BioJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.0010/10/2025CABACabaletta BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.0010/8/2025ADAPAdaptimmune TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BCRXBioCryst PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CABACabaletta BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025BCRXBioCryst PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/1/2025BCRXBioCryst PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ In-Line$8.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$65.09M0.30N/AN/A$0.05 per share1.45BCRXBioCryst Pharmaceuticals$557.51M2.67N/AN/A($2.30) per share-3.08CABACabaletta BioN/AN/AN/AN/A$3.12 per shareN/AHARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12PDLIPDL BioPharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%11/12/2025 (Estimated)BCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/AN/A-6.41%N/A-1.78%11/3/2025 (Estimated)CABACabaletta Bio-$115.86M-$2.71N/AN/AN/AN/A-92.11%-74.08%11/13/2025 (Estimated)HARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/APDLIPDL BioPharmaN/A$0.1913.00∞N/AN/AN/AN/AN/ALatest HARP, BCRX, ADAP, CABA, and PDLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025CABACabaletta Bio-$0.52N/AN/AN/AN/AN/A11/12/2025Q3 2025ADAPAdaptimmune Therapeutics-$0.09N/AN/AN/A$12.31 millionN/A11/3/2025Q3 2025BCRXBioCryst Pharmaceuticals$0.05N/AN/AN/A$162.91 millionN/A8/13/2025Q2 2025ADAPAdaptimmune Therapeutics-$0.15-$0.11+$0.04-$0.11$11.04 million$13.68 million8/7/2025Q2 2025CABACabaletta Bio-$0.71-$0.73-$0.02-$0.73$4.17 millionN/A8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/APDLIPDL BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune TherapeuticsN/A1.521.29BCRXBioCryst PharmaceuticalsN/A2.252.22CABACabaletta BioN/A4.784.78HARPHarpoon TherapeuticsN/A1.891.89PDLIPDL BioPharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%BCRXBioCryst Pharmaceuticals85.88%CABACabaletta BioN/AHARPHarpoon Therapeutics74.01%PDLIPDL BioPharmaN/AInsider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%BCRXBioCryst Pharmaceuticals5.10%CABACabaletta Bio11.25%HARPHarpoon Therapeutics17.00%PDLIPDL BioPharma11.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million232.08 millionOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableCABACabaletta Bio5091.47 million81.18 millionOptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionablePDLIPDL BioPharma109N/AN/AOptionableHARP, BCRX, ADAP, CABA, and PDLI HeadlinesRecent News About These CompaniesGT Biopharma Inc GTBPFebruary 23, 2024 | morningstar.comMHealth Winners & Losers: MaxygenOctober 24, 2023 | thestreet.comPDLI Historical DataOctober 18, 2023 | investing.comPDL stabbed by fellow inmateSeptember 23, 2023 | philstar.comPABVC - ABVC BioPharma, Inc.June 28, 2023 | finance.yahoo.comRDHL - RedHill Biopharma Ltd.June 23, 2023 | finance.yahoo.comIntravenous Therapy for Hypertensive Emergencies, Part 2May 9, 2023 | medscape.comMCheap Flights from Nuremberg to Ponta DelgadaApril 21, 2023 | skyscanner.netSCheap Flights from London to Ponta DelgadaApril 16, 2023 | skyscanner.netSIntravenous Therapy for Hypertensive Emergencies, Part 1April 12, 2023 | medscape.comMLABPMarch 12, 2023 | seekingalpha.comPolaris Digitech Partners Google to Enhance Businesses Location VisibilityMarch 11, 2023 | thisdaylive.comTCasdin Leads a Biopharma SurgeFebruary 23, 2023 | institutionalinvestor.comIA Persons Deprived of Liberty (PDL) interacts with his pet mouse inside the jailJanuary 15, 2023 | msn.comPDL BioPharma Stock To Go Ex-dividend Monday (PDLI)January 4, 2023 | thestreet.comPDL BioPharma Stock To Go Ex-dividend Tomorrow (PDLI)December 14, 2022 | thestreet.comKeeping Biogen Idec Innovative: Jim Mullen Interview (Part 2)August 18, 2022 | xconomy.comXCramer's 'Mad Money' Recap: Politics Is OverratedAugust 6, 2022 | thestreet.comSteris (STE)May 21, 2022 | forbes.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Tesla: 3 Reasons October’s Earnings Will Make or Break the StockBy Sam Quirke | September 23, 2025Analysts Think These Stocks Could More Than DoubleBy Nathan Reiff | October 22, 20255 Stocks and ETFs to Weather Volatility as Trade Tensions RiseBy Ryan Hasson | October 13, 2025HARP, BCRX, ADAP, CABA, and PDLI Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.07 +0.02 (+49.18%) Closing price 04:00 PM EasternExtended Trading$0.07 +0.00 (+0.55%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.BioCryst Pharmaceuticals NASDAQ:BCRX$7.08 +0.09 (+1.29%) Closing price 04:00 PM EasternExtended Trading$7.15 +0.07 (+0.99%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Cabaletta Bio NASDAQ:CABA$2.45 -0.29 (-10.58%) Closing price 04:00 PM EasternExtended Trading$2.50 +0.04 (+1.84%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Harpoon Therapeutics NASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.PDL BioPharma NASDAQ:PDLIPDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
